Objective: The aim of this study was to evaluate the prevalence of aspirin non-responsiveness using whole blood multiple electrode aggregometry and to investigate the role of different clinical and laboratory variables associated with the lack of response. Methods: The present study included 116 aspirin treated patients presented with acute coronary syndromes or stroke. Response to aspirin was assessed by impedance aggregometry using arachidonic acid as agonist, in a final concentration of 0.5 mM (ASPI test). Results: In our data set 81% (n=94) were responders and 19% (n=22) non-responders showing high-on-aspirin platelet reactivity. Correlation analysis showed that the ward of admittance, low-density lipoproteins (LDL), concomitant antibiotic treatment, beta-adrenergic receptor blockers, history of myocardial infarction as well as PCI performed on Cardiology patients have different degrees of association with aspirin response. Conclusion: Concomitant treatment with beta-adrenergic receptor inhibitors, history of myocardial infarction and Cardiology ward admittance significantly increased the chance of responding to aspirin treatment whereas antibiotic therapy and low-density lipoproteins cholesterol seemed to increase the risk of high-on-aspirin residual platelet reactivity.
Introduction
Aspirin plays a central role in treatment and prevention of atherothrombotic events like stroke and acute coronary syndromes [1] [2] [3] . Randomised clinical trials have shown that aspirin reduces the risk of new atherothrombotic events by 25-30% [4] . However, 12.5% of patients develop a recurrent ischemic event during the two-year followup, indicating that aspirin is ineffective in certain patients [5] .
Platelet aggregation measurements have shown large variability in platelet response in case of aspirin treated patients, 1-60% of patients demonstrating insufficient platelet inhibition [4] . This variation can be partially explained by differences in methods and cut-off values used to evaluate and define aspirin response, as well as by the varying extent of compliance [5] .
Patients who despite treatment present a normal platelet aggregation are often referred to as aspirin non-responders, having high-on-treatment platelet reactivity or aspirin resistance [4] . With regard to aspirin resistance, the following situations have been previously reported: laboratory resistance (non-responsiveness) -evaluated using a laboratory test, chemical ("true") resistance -the inability of aspirin to acetylate platelet cyclooxygenase-1, and clinical resistance (aspirin ineffectiveness) -development of acute thrombotic events during treatment [6] . Taking into consideration that various studies demonstrated an important inhibition of thromboxane (TX) B 2 production in aspirin treated patients detected as non-responders in platelet function tests, the term "resistance" seems inappropriate in these cases [4] .
The aim of the study was to investigate the prevalence of aspirin non-responsiveness in patients treated with aspirin using whole blood multiple electrode aggregometry.
Methods

Subjects
In the present study 116 patients with acute coronary syndromes or ischemic stroke were enrolled between September 2014 and June 2015.
The study was conducted in agreement with the Declaration of Helsinki.
The study protocol was approved by the Ethics review boards of the Emergency Institute for Cardiovascular Diseases and Transplantation Tîrgu Mureș and by Emergency County Hospital Tîrgu Mureș (nr. 4123/04.08.2014 and nr. 12247/13.06.2014) and all patients gave their written informed consent.
Plain aspirin was administered following the current guidelines for stroke and acute coronary syndromes for at least five days before analysis [7] . Compliance was investigated by a face-to-face interview.
Exclusion criteria included non-compliance, use of nonsteroidal anti-inflammatory drugs or GPIIb/IIIa receptor antagonists, documented absence of GPIIb/IIIa receptor, thrombocytopenia (platelet count below 100.000/µL) or thrombocytosis (platelet count over 450.000 /µL), severe renal and liver dysfunction, major surgical procedure in the previous week before enrolment.
Blood Sampling
Samples were collected into double walled Hirudin tubes (Roche Diagnostics) and analysed within 0.5 -3 hours of blood collection.
Platelet function assessment
Platelet aggregation was measured by Multiplate® aggregometry (Roche Diagnostics) following the manufacturer's instructions. Th e agonist used was arachidonic acid (a COX-1 specifi c method [4] ) in a fi nal concentration of 0.5 mM (ASPI test). Results were plotted as an area under the curve (AUC) and consequently interpreted.
Statistical analysis
IBM® SPSS® Statistics v22.0 (Armonk, NY, USA) software was used for statistical analysis. Th e chosen alpha value for statistical signifi cance was 0.05 (α=0.05). Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range (for non-parametric data) whereas categorical data was represented as counts and percentage. Th e assumption of normal distribution for the continuous variables was verifi ed. Comparisons between groups were performed with the 2-tailed t-Test or the Mann-Whitney U test, as appropriate. Categorical variables were compared using the Chi-square (χ 2 ) test (or Fisher's exact test for less than 5expected counts). To assess the association between aspirin response and diff erent demographic, clinical and laboratory variables we performed correlation analysis using Pearson's product-moment or Spearman's rank-order, as appropriate. Phi correlation was used for binary data.
All independent variables with r (or phi) value ≥ (±) 0.1 that also achieved statistical signifi cance (p>0.05) were included in a univariate regression analysis.
Th e binary logistic regression analysis was performed with the dependent variable obtained after dichotomizing by AUC units resulted from ASPI test at the cut-off of 40 U and considering the patients as responders (AUC<40 U) or non-responders (AUC≥40 U) to aspirin therapy.
Results
In our data set 81% (n=94) were responders and 19% (n=22) non-responders showing high-on-aspirin platelet reactivity. Platelet aggregation curves for both responders and non-responders to aspirin therapy are illustrated in Figure 1 and Figure 2 .
Baseline characteristics of the study population in addition to the comparisons between aspirin responders and non-responders are summarized in Table I .
Correlation analysis showed that in our data set the ward where patients were admitted, low-density cholesterol (LDL-C), concomitant antibiotic treatment, beta-adrenergic receptor blockers and a history of myocardial infarction as well as PCI performed on Cardiology patients, have diff erent degrees of association with aspirin response (Table II) . The univariate regression analysis showed that betablocker treatment increases the probability of a patient responding to aspirin treatment by more than 4 times (OR 4.46, p=0.003) while explaining a little over 10% in response variability (R 2 =0.124). A similar statistical behaviour was observed for the history of myocardial infarction that increased the chance of being a responder by almost 4.7 times (OR 4.69, p=0.046) and explains 7.5% of the observed variability (R 2 =0.075). The ward where the patients were admitted influenced significantly the probability of response, a patient from the Cardiology ward being 4.7 times more likely to respond to aspirin therapy than Neurology patients (OR 4.7, p=0.003), accounting for 13% of variability (R 2 =0.13) (Figure 3 ). Also, among Cardiology patients, if they received interventional coronary therapy (PCI), the chance of falling in the responder category was 9.5 times higher (OR 9.5, p=0.032).
As for patients receiving antibiotic treatment the chance of being non-responder was 5 times higher compared to those without such treatment (OR 0.199, p=0.006), which accounts for 9.5% of variability (R 2 =0.095). Elevated low-density lipoproteins blood levels slightly increased the chance of falling in the non-responder category but to a much less extent (OR 0.98, p=0.005) accounting for 21.7% of observed variability (R 2 =0.217) (Table III) .
Discussion
Multiple methods have been used to evaluate the antiplatelet effect of aspirin, such as measuring the cyclooxygenase-1 (COX-1)-dependent platelet aggregation and throm- boxane levels in serum or urine. Several of these studies showed a substantial inhibition of thromboxane (TX) B2 production in aspirin-treated patients -even in those with high platelet reactivity. Thus, the term high-on-aspirin residual platelet reactivity might describe more appropriately this phenomenon as opposed to "aspirin resistance". COX-1 inhibition affects only one of the several pathways involved in platelet activation, thus these platelets can still be activated by other platelet agonists like thrombin, collagen or ADP [4] . Several studies investigating the causes of high-on aspirin platelet reactivity gave different results. Concomitant administration with non-steroidal anti-inflammatory drugs, statins, selective serotonin re-uptake inhibitors, proton pump inhibitors and angiotensin receptor blockers has been correlated with an ineffective aspirin response [8] [9] [10] [11] .
Our data did not show any effect on platelet reactivity for drugs such as statins, selective serotonin re-uptake inhibitors, proton pump inhibitors or ACE inhibitors. In contrast to these findings, Feher et al. reported that patients taking ACE inhibitors were more likely to be aspirin responders, whereas those treated with statins had more chances of falling into the non-responder category [12] . The contradictory findings may be explained by the differences regarding the number of subjects included in studies.
In the univariate logistic regression analysis of the present study, use of antibiotics or beta-blockers, LDL levels, present history of myocardial infarction, PCI performed and ward were significantly different between aspirin nonresponders and aspirin sensitive patients.
As for antibiotic therapy, our data suggest that it could contribute to aspirin "resistance", and to the best knowledge of the authors, this might be the first report of such an effect.
Beta-adrenergic receptor inhibitors (beta-blockers) have the opposite effect, increasing the chance of being a re- sponder by more than 4 times, these being in contrast with results reported by Uzun et al. [13] . A similar effect was seen for the ward where patients were admitted, with Cardiology patients being significantly more prone to be responders than those in Neurology. The results of this study regarding the association between LDL levels and aspirin response were comparable with the results of previous studies [13] [14] [15] [16] .
The clinical relevance of high on-aspirin platelet reactivity has been previously addressed, but due to the inconsistent findings current guidelines do not recommend the routine use of platelet function tests in aspirin-treated patients, although this might have a beneficial role in high-risk patients such as those with advanced stage coronary artery disease (triple vessel disease, left main severe stenosis), diffuse atherosclerotic disease, diabetes mellitus and those with chronic renal disease undergoing percutaneous coronary intervention. Also, when pharmacodynamic interactions with other drugs are suspected (as it often is the case in critical care facilities) this approach might provide a way to correctly assess the adequacy of platelet inhibition.
Study limitations
Thromboxane B 2 serum levels were not measured, therefore compliance had to be assumed based on oral interview.
Conclusions
Concomitant therapy with beta-adrenergic receptor inhibitors, history of myocardial infarction and patients admitted to the Cardiology ward had a significantly higher chance of falling into the responder category, whereas antibiotic therapy and to a lesser extent, low-density lipoprotein cholesterol blood levels, seemed to increase the risk of high-on-aspirin residual platelet reactivity.
Baseline clinical and laboratory data might provide a useful tool for identifying some of the patients that exhibit high platelet reactivity but inconsistent findings and sometimes conflicting reports call for a careful interpretation.
While we wait for definitive trials, a predictive prognostic algorithm is necessary to individualize antiplatelet therapy.
